Table 4. Results of trans-hydroxy praziquantel (TPZQ) in the tested matrices in the course of the experiment.
| Day | Water (μg/l) |
Plasma (μg/l) |
Hepatopancreas (μg/kg) |
Kidney (μg/kg) |
Muscle (μg/kg) |
Gill (μg/kg) |
Skin (μg/kg) |
| 0 | < 0.26*d | < 9.7*c | < 10.0*d | < 12.0*b | < 11.0*b | < 11.0*b | < 11.0*c |
| 1 | 15.2 ± 1.0 (15.2)c |
601.6 ± 280.2 (681.0)a |
426.7 ± 213.1 (411.0)ab |
473.9 ± 168.5 (439.0)a |
207.4 ± 75.5 (172.0)a |
1 440.9 ± 700.5 (1 400.0)a |
215.8 ± 79.4 (246.0)a |
| 2 | 17.1 ± 2.6 (16.5)c |
368.0 ± 94.1 (368.0)b |
312.4 ± 67.4 (317.0)bc |
283.9 ± 62.5 (263.0)a |
175.7 ± 34.6 (180.0)a |
1 161.9 ± 534.3 (1 050.0)a |
129.9 ± 28.9 (138.0)b |
| 3 | 36.6 ± 4.9 (39.0)b |
455.6 ± 109.7 (473.0)ab |
284.9 ± 59.1 (314.0)c |
370.9 ± 86.3 (372.0)a |
183.1 ± 49.9 (158.0)a |
1 356.6 ± 378.1 (1 460.0)a |
129.1 ± 40.0 (126.0)b |
| 4 | 50.8 ± 5.4 (51.9)a |
402.6 ± 38.3 (406.0)b |
458.4 ± 55.8 (462.0)a |
244.1 ± 49.9 (232.0)a |
165.9 ± 46.9 (176.0)a |
1 319.6 ± 294.3 (1 390.0)a |
195.3 ± 28.8 (183.0)a |
| 10 | 15.6 ± 1.6 (16.5)c |
< 9.7*c | 48.4 ± 12.8 (49.2)d |
< 12.0*b | < 11.0*b | < 11.0*b | < 11.0*c |
| 16 | 1.0 ± 0.2 (0.8)d |
< 9.7*c | 13.6 ± 1.9 (13.3)d |
< 12.0*b | < 11.0*b | < 11.0*b | < 11.0*c |
| 23 | < 0.26*d | < 9.7*c | < 10.0*d | < 12.0*b | < 11.0*b | < 11.0*b | < 11.0*c |
| 30 | < 0.26*d | < 9.7*c | < 10.0*d | < 12.0*b | < 11.0*b | < 11.0*b | < 11.0*c |
a–dStatistically significant differences in the concentrations between the sampling days are indicated by different alphabetic superscript letters (P < 0.05); Data are presented as the mean ± standard deviation; the median value is given in the brackets; *Results were below the limit of detection, half of this particular limit of detection was used for the statistical analysis; †Descriptive characteristics were calculated only from the positive samples